FINANCIAL ASSISTANCE FOR YOUR PATIENTS

Options are available for commercially insured, Medicare Part D, and uninsured patients.

For eligible commercially insured patients

ORGOVYX Copay Assistance Program Card

Pay as little as $10 per month

With the ORGOVYX Copay Assistance Program, eligible commercially insured patients pay as little as $10 per month.* Learn more about the eligibility criteria for the ORGOVYX Copay Assistance Program by calling 1-833-ORGOVYX (1-833-674-6899). See Terms and Conditions below.

To enroll or re-enroll in the ORGOVYX Copay Assistance Program, click below.
The ORGOVYX Support Program may be able to help those patients who are not eligible for an ORGOVYX Savings Card or need additional assistance. Call the ORGOVYX Support Program at 1-833-ORGOVYX (1-833-674-6899).

ORGOVYX COPAY ASSISTANCE PROGRAM: TERMS AND CONDITIONS

*The ORGOVYX Copay Assistance Program (“Program”) is for eligible patients with commercial prescription insurance for ORGOVYX. With this Program, eligible patients will pay as little as $10 per monthly ORGOVYX prescription. Patient must enroll in the Program by visiting www.ORGOVYX.com or by calling 1-833-ORGOVYX (833-674-6899). Card must be activated before use. This Program may not be redeemed more than once every 21 days. The Program is not valid for patients whose prescription claims are reimbursed, in whole or in part, by any state or federal government program, including, but not limited to, Medicaid, Medicare, Medigap, Department of Defense (DoD), Veterans Affairs (VA), TRICARE, Puerto Rico Government Insurance, or any state patient or pharmaceutical assistance program. Offer is not valid for cash-paying patients. Patient must be a resident of the US, Puerto Rico, or US Territories. This Program is void where prohibited by state law and on the date an AB rated generic equivalent for ORGOVYX becomes available. Certain rules and restrictions apply. This card is not insurance. This offer cannot be combined with any other coupon, discount, prescription savings card, or other offer. This offer is not conditioned on any past or future purchase, including refills. Patient and participating pharmacists agree not to seek reimbursement for all, or any part of the benefit received by the patient through this Program. Patient and participating pharmacists agree to report the receipt of Program benefits to any insurer or other third party who pays for or reimburses any part of the prescription filled using the Card, as may be required by such insurer or third party. Myovant Sciences reserves the right to revoke, rescind, or amend this offer without notice.

Patients includes Commercial, Medicare and Medicaid. Formulary data are provided by MMIT, LLC as of April, 2022.

For Medicare Part D PATIENTS

Your patients may qualify for additional financial support resources. Learn more by calling 1-833-ORGOVYX (1-833-674-6899).

Did you know that some Medicare Part D patients receive extra help for branded prescriptions and are eligible for reduced copays?1

For eligible uninsured patients

Through the Myovant Patient Assistance Program, eligible patients may be able to get ORGOVYX at no cost. Learn more about the eligibility criteria for the Myovant Patient Assistance Program by calling 1-833-ORGOVYX (1-833-674-6899).

MYOVANT SCIENCES PATIENT ASSISTANCE PROGRAM: TERMS AND CONDITIONS

The Myovant Sciences Patient Assistance Program (“Program") provides ORGOVYX at no cost to eligible patients who are prescribed ORGOVYX for an FDA-approved indication. Patients and prescribers must complete the ORGOVYX Support Program enrollment form, and prescribers must provide a Patient Assistance Program prescription. Patients must meet Program eligibility requirements, which include, but are not limited to, lack of insurance coverage for ORGOVYX, financial criteria and income evaluation, and patients must be residents of the United States and US Territories. Program requires annual re-evaluation and re-enrollment for continued participation. Patients may be asked to reverify insurance coverage status during the course of the Program. Patient and participating prescribers agree not to seek reimbursement for all, or any part of, the free product received by the patient through this Program. Patients may not count the free product received from the ORGOVYX Support Program as an expense incurred for purposes of determining out-of-pocket costs for any plan, including true out-of-pocket costs (“TrOOP”) for purposes of calculating the out-of-pocket threshold for Medicare Part D plans. Government health insured patients who meet the Program eligibility criteria are eligible to receive free product for the entire coverage year, and Myovant Sciences will notify patients’ government health insurance plans that the patient is enrolled in the Program. No purchase necessary. Program is not health insurance, nor is participation a guarantee of insurance coverage. Other limitations may apply. Myovant Sciences reserves the right to rescind, revoke, or amend the Program and discontinue support at any time without notice.

88% of patients are covered nationwide, and 99% of Medicare patients are covered for ORGOVYX.2
See formulary coverage in your area

IMPORTANT SAFETY INFORMATION & INDICATION

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

QT/QTc Interval Prolongation: Androgen deprivation therapy, such as ORGOVYX may prolong the QT/QTc interval. Providers should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, or frequent electrolyte abnormalities and in patients taking drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected. Consider periodic monitoring of electrocardiograms and electrolytes.

Embryo-Fetal Toxicity: The safety and efficacy of ORGOVYX have not been established in females. Based on findings in animals and mechanism of action, ORGOVYX can cause fetal harm and loss of pregnancy when administered to a pregnant female. Advise males with female partners of reproductive potential to use effective contraception during treatment and for 2 weeks after the last dose of ORGOVYX

Laboratory Testing: Therapy with ORGOVYX results in suppression of the pituitary gonadal system. Results of diagnostic tests of the pituitary gonadotropic and gonadal functions conducted during and after ORGOVYX may be affected. The therapeutic effect of ORGOVYX should be monitored by measuring serum concentrations of prostate-specific antigen (PSA) periodically. If PSA increases, serum concentrations of testosterone should be measured.

Adverse Reactions

Serious adverse reactions occurred in 12% of patients receiving ORGOVYX. Serious adverse reactions in ≥0.5% of patients included myocardial infarction (0.8%), acute kidney injury (0.6%), arrhythmia (0.6%), hemorrhage (0.6%), and urinary tract infection (0.5%). Fatal adverse reactions occurred in 0.8% of patients receiving ORGOVYX including metastatic lung cancer (0.3%), myocardial infarction (0.3%), and acute kidney injury (0.2%). Fatal and non-fatal myocardial infarction and stroke were reported in 2.7% of patients receiving ORGOVYX.

Most common adverse reactions (≥10%) and laboratory abnormalities (≥15%) in patients receiving ORGOVYX were hot flush (54%), glucose increased (44%), triglycerides increased (35%), musculoskeletal pain (30%), hemoglobin decreased (28%), alanine aminotransferase increased (27%), fatigue (26%), aspartate aminotransferase increased (18%), constipation (12%), and diarrhea (12%).

Drug Interactions

Co-administration of ORGOVYX with a P-gp inhibitor increases the area under the curve (AUC) and maximum concentration (Cmax) of ORGOVYX, which may increase the risk of adverse reactions associated with ORGOVYX. Avoid co-administration of ORGOVYX with oral P-gp inhibitors. If co-administration is unavoidable, take ORGOVYX first, separate dosing by at least 6 hours, and monitor patients more frequently for adverse reactions. Treatment with ORGOVYX may be interrupted for up to 2 weeks for a short course of treatment with certain P-gp inhibitors. If treatment with ORGOVYX is interrupted for more than 7 days, resume administration of ORGOVYX with a 360 mg loading dose on the first day, followed by 120 mg once daily.

Co-administration of ORGOVYX with a combined P-gp and strong CYP3A inducer decreases the AUC and Cmax of ORGOVYX, which may reduce the effects of ORGOVYX. Avoid co-administration of ORGOVYX with combined P-gp and strong CYP3A inducers. If co-administration is unavoidable, increase the ORGOVYX dose to 240 mg once daily. After discontinuation of the combined P-gp and strong CYP3A inducer, resume the recommended ORGOVYX dose of 120 mg once daily.

INDICATION

ORGOVYX is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of adult patients with advanced prostate cancer.

Please see full Prescribing Information for ORGOVYX.